CA2680824C - Treatment of leaky or damaged tight junctions and enhancing extracellular matrix - Google Patents

Treatment of leaky or damaged tight junctions and enhancing extracellular matrix Download PDF

Info

Publication number
CA2680824C
CA2680824C CA2680824A CA2680824A CA2680824C CA 2680824 C CA2680824 C CA 2680824C CA 2680824 A CA2680824 A CA 2680824A CA 2680824 A CA2680824 A CA 2680824A CA 2680824 C CA2680824 C CA 2680824C
Authority
CA
Canada
Prior art keywords
seq
self
xaa
peptides
assembling
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2680824A
Other languages
English (en)
French (fr)
Other versions
CA2680824A1 (en
Inventor
Rutledge Ellis-Behnke
Stephen Richard Kelly
Terrence W. Norchi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Arch Biosurgery Inc
Original Assignee
Arch Biosurgery Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arch Biosurgery Inc filed Critical Arch Biosurgery Inc
Publication of CA2680824A1 publication Critical patent/CA2680824A1/en
Application granted granted Critical
Publication of CA2680824C publication Critical patent/CA2680824C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1008—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
CA2680824A 2007-03-14 2008-03-14 Treatment of leaky or damaged tight junctions and enhancing extracellular matrix Active CA2680824C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US89487207P 2007-03-14 2007-03-14
US60/894,872 2007-03-14
PCT/US2008/057104 WO2008113030A2 (en) 2007-03-14 2008-03-14 Treatment of leaky or damaged tight junctions and enhancing extracellular matrix

Publications (2)

Publication Number Publication Date
CA2680824A1 CA2680824A1 (en) 2008-09-18
CA2680824C true CA2680824C (en) 2018-06-26

Family

ID=39462068

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2680824A Active CA2680824C (en) 2007-03-14 2008-03-14 Treatment of leaky or damaged tight junctions and enhancing extracellular matrix

Country Status (7)

Country Link
US (2) US9415084B2 (enExample)
EP (1) EP2146733B1 (enExample)
JP (4) JP2010521495A (enExample)
CA (1) CA2680824C (enExample)
DK (1) DK2146733T3 (enExample)
ES (1) ES2854674T3 (enExample)
WO (1) WO2008113030A2 (enExample)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2427565T3 (es) 2005-04-25 2013-10-31 Massachusetts Institute Of Technology Péptidos autoensambladores para promover la hemostasia
US9162005B2 (en) * 2005-04-25 2015-10-20 Arch Biosurgery, Inc. Compositions for prevention of adhesions and other barrier applications
WO2007082305A2 (en) 2006-01-12 2007-07-19 Massachusetts Institute Of Technology Biodegradable elastomers
US8168181B2 (en) 2006-02-13 2012-05-01 Alethia Biotherapeutics, Inc. Methods of impairing osteoclast differentiation using antibodies that bind siglec-15
CA2822302A1 (en) 2006-02-13 2007-08-23 Alethia Biotherapeutics Inc. Methods of impairing osteoclast differentiation
HUE037994T2 (hu) 2006-04-25 2018-09-28 Massachusetts Inst Technology Készítmények és eljárások szennyezõ anyagok, testfolyadékok vagy más anyagok mozgásának befolyásolására és/vagy más fiziológiai állapotok befolyásolására
JP5385284B2 (ja) * 2007-09-11 2014-01-08 モンドバイオテック ラボラトリーズ アクチエンゲゼルシャフト 治療剤としてのグルテンエキソルフィンＣ（ＧｌｕｔｅｎＥｘｏｒｐｈｉｎＣ）の使用
WO2009040020A1 (en) * 2007-09-11 2009-04-02 Mondobiotech Laboratories Ag Amylin as a therapeutic agent
WO2009043441A1 (en) * 2007-09-11 2009-04-09 Mondobiotech Laboratories Ag D-ala-gln-octadecyl ester as a therapeutic agent
EP3238749B2 (en) 2008-10-06 2025-06-04 3-D Matrix, Ltd. Tissue plug
US20110200560A1 (en) * 2009-05-26 2011-08-18 Massachusetts Institute Of Technology Non-ionic self-assembling peptides and uses thereof
WO2011072482A1 (en) 2009-12-14 2011-06-23 The University Of Hong Kong Nano cancer barrier device(ncbd) to immobilize and inhibit the division of metastic cancer stem cells
US9084752B2 (en) * 2009-12-14 2015-07-21 The University Of Hong Kong Compositions and methods for controlling proliferation and differentiation of cells
WO2011084509A1 (en) * 2009-12-15 2011-07-14 Massachusetts Institute Of Technology Endothelial basement membrane targeting peptide ligands
WO2012008967A1 (en) * 2010-07-16 2012-01-19 Massachusetts Institute Of Technology Self-assembling peptides incorporating modifications and methods of use thereof
US8741833B2 (en) * 2010-07-16 2014-06-03 Massachusetts Institute Of Technology Self-assembling peptides incorporating modifications and methods of use thereof
JP5934710B2 (ja) * 2010-10-07 2016-06-15 マサチューセッツ インスティテュート オブ テクノロジー ローレンツ力直動型の無針式ジェット注射システムを用いた固形物および／または流体の供給
US8546338B2 (en) 2010-12-08 2013-10-01 Johnson & Johnson Consumer Companies, Inc. Self-assembling hydrogels based on dicephalic peptide amphiphiles
DK2654793T3 (en) 2010-12-21 2017-12-18 Leidos Inc Methods and compositions for wound treatment.
EP3466964A1 (en) 2012-07-06 2019-04-10 3-D Matrix Ltd. Fill-finish process for peptide solutions
ES2723885T3 (es) 2012-07-19 2019-09-03 Daiichi Sankyo Co Ltd Anticuerpos anti-Siglec-15
EP2698162A1 (en) 2012-08-15 2014-02-19 Credentis AG Method for producing a composition for treating a tooth lesion
US9241891B2 (en) 2012-10-30 2016-01-26 The Procter & Gamble Company Personal care compositions comprising self-assembling peptides
SG11201508032RA (en) * 2013-03-30 2015-10-29 Glytech Inc (sugar chain)-polypeptide complex
CN105658252A (zh) * 2013-08-22 2016-06-08 阿奇生物外科有限公司 用于控制流体移动的可植入网状物
US10314776B2 (en) 2013-09-25 2019-06-11 Credentis Ag Dental care product for tooth whitening
EP2853256A1 (en) 2013-09-25 2015-04-01 Credentis AG Dental care product for tooth whitening
WO2015053338A1 (ja) * 2013-10-08 2015-04-16 学校法人東京理科大学 カチオン性ペプチドおよびそれを含む医薬組成物
CN117138022A (zh) 2014-03-10 2023-12-01 三维矩阵有限责任公司 自组装肽组合物
EP3628337B1 (en) 2014-03-10 2025-05-28 3-D Matrix, Ltd. Sterilization and filtration of peptide compositions
WO2015138478A1 (en) 2014-03-10 2015-09-17 3-D Matrix, Ltd. Autoassembling peptides for the treatment of pulmonary bulla
WO2015145797A1 (ja) * 2014-03-28 2015-10-01 大塚化学株式会社 止血用医薬組成物
KR20180102583A (ko) * 2015-12-18 2018-09-17 가부시끼가이샤 쓰리디 매트릭스 지혈용 조성물 및 지혈용 조성물을 이용한 지혈방법
US10814038B2 (en) 2016-01-06 2020-10-27 3-D Matrix, Ltd. Combination compositions
EP3248590A1 (en) 2016-05-24 2017-11-29 Credentis AG Personal dental care product for caries treatment
EP3248591A1 (en) 2016-05-24 2017-11-29 Credentis AG Method and product for caries treatment
US20190060506A1 (en) * 2017-08-22 2019-02-28 The Board Of Trustees Of The Leland Stanford Junior University Elafin Incorporated Biomaterials for the Treatment of Chronic Tissue Ulcers
EP3723726A1 (en) 2017-12-15 2020-10-21 3-D Matrix, Ltd. Surfactant peptide nanostructures and uses in drug delivery
EP3738603A4 (en) * 2018-01-11 2022-03-09 The University of Tokyo NTCP INHIBITOR
CN112165954A (zh) 2018-03-23 2021-01-01 阿奇生物外科有限公司 用于治疗眼病的sap和拟肽
WO2019183625A1 (en) 2018-03-23 2019-09-26 Arch Biosurgery, Inc. Sap and peptidomimetic compositions for reducing symptoms of inflammation
JP7437315B2 (ja) * 2018-10-05 2024-02-22 学校法人 久留米大学 腸管における潰瘍または瘻孔の治療または予防のための医薬組成物
WO2020252003A1 (en) 2019-06-13 2020-12-17 Hollister Incorporated Reusable urinary catheter products
US12440644B2 (en) 2019-06-25 2025-10-14 Hollister Incorporated Reusable urinary catheter products
EP3831360A1 (en) 2019-12-04 2021-06-09 Credentis AG Personal dental care product for preventing demineralisation
CN111116717B (zh) * 2020-01-03 2021-10-29 中国科学院大学温州研究院(温州生物材料与工程研究所) 含有n-甲基-d-葡糖胺单元的糖肽水凝胶、制备方法及其应用
US12390552B2 (en) 2020-01-13 2025-08-19 Arch Biosurgery, Inc. Self-assembling peptide gel formulation and methods of use
US11154470B1 (en) 2020-07-31 2021-10-26 vVardis AG Anti-inflammatory and senolytic dental care product with tooth whitening characteristics
WO2022173926A1 (en) * 2021-02-10 2022-08-18 3-D Matrix, Ltd. Pharmaceutical composition containing specific self-assembling peptide rada16 for treating or preventing lower gastrointestinal diseases such as inflammatory bowel disease
WO2024128081A1 (ja) * 2022-12-16 2024-06-20 東亞合成株式会社 合成ペプチド及び構築物
CN116789854B (zh) * 2023-06-08 2024-04-02 东北农业大学 兼具细菌捕获与抑菌功能的纳米抗菌肽及制备方法和应用
WO2025226888A1 (en) * 2024-04-26 2025-10-30 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Ecm-derived injectable embolic for permanent treatment of cerebral aneurysms

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4098728A (en) 1976-01-02 1978-07-04 Solomon Rosenblatt Medical surgical sponge and method of making same
US4211227A (en) 1978-07-03 1980-07-08 The Kendall Company Surgical sponge material
US4272398A (en) 1978-08-17 1981-06-09 The United States Of America As Represented By The Secretary Of Agriculture Microencapsulation process
US4636208A (en) 1984-10-05 1987-01-13 Ewald Rath Surgical sponge
US4829000A (en) 1985-08-30 1989-05-09 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Reconstituted basement membrane complex with biological activity
US4861627A (en) 1987-05-01 1989-08-29 Massachusetts Institute Of Technology Preparation of multiwall polymeric microcapsules
US5019646A (en) 1987-08-25 1991-05-28 Regents Of The University Of Minnesota Polypeptides with fibronectin activity
US5843156A (en) 1988-08-24 1998-12-01 Endoluminal Therapeutics, Inc. Local polymeric gel cellular therapy
CA2122041A1 (en) 1989-12-04 1993-04-29 Kenneth Kensey Plug device for sealing openings and method of use
US5180375A (en) 1991-05-02 1993-01-19 Feibus Miriam H Woven surgical drain and woven surgical sponge
US5222974A (en) 1991-11-08 1993-06-29 Kensey Nash Corporation Hemostatic puncture closure system and method of use
US5955343A (en) * 1992-12-28 1999-09-21 Massachusetts Institute Of Technology Stable macroscopic membranes formed by self-assembly of amphiphilic peptides and uses therefor
US5670483A (en) 1992-12-28 1997-09-23 Massachusetts Insititute Of Technology Stable macroscopic membranes formed by self-assembly of amphiphilic peptides and uses therefor
US5645565A (en) 1995-06-13 1997-07-08 Ethicon Endo-Surgery, Inc. Surgical plug
US6368877B1 (en) 1997-06-25 2002-04-09 Massachusetts Institute Of Technology Self-assembling peptide surfaces for cell patterning and interactions
US6235340B1 (en) 1998-04-10 2001-05-22 Massachusetts Institute Of Technology Biopolymer-resistant coatings
US6333194B1 (en) 1999-01-19 2001-12-25 The Children's Hospital Of Philadelphia Hydrogel compositions for controlled delivery of virus vectors and methods of use thereof
WO2000063079A1 (en) 1999-04-15 2000-10-26 Ultracell Medical Technologies Of Connecticut, Inc. Method for producing surgical sponge device and product thereof
US6844324B1 (en) 1999-11-12 2005-01-18 Massachusetts Institute Of Technology Modular peptide mediated intracellular delivery system and uses therefore
US6953656B2 (en) 2000-07-14 2005-10-11 Massachusetts Institute Of Technology Direct, externally imposed control of polypeptides
US6953659B2 (en) 2000-07-14 2005-10-11 Massachusetts Institute Of Technology Direct, externally imposed control of nucleic acids
US6846319B2 (en) 2000-12-14 2005-01-25 Core Medical, Inc. Devices for sealing openings through tissue and apparatus and methods for delivering them
EP1367961B1 (en) 2001-02-06 2008-12-31 Massachusetts Institute Of Technology Peptide scaffold encapsulation of tissue cells and uses thereof
US7449180B2 (en) 2001-02-06 2008-11-11 John Kisiday Macroscopic scaffold containing amphiphilic peptides encapsulating cells
US7179784B2 (en) 2001-07-10 2007-02-20 Massachusetts Institute Of Technology Surfactant peptide nanostructures, and uses thereof
WO2003052117A2 (en) 2001-09-19 2003-06-26 Massachusetts Institute Of Technology Methods and products related to non-viral transfection
AU2003222167A1 (en) 2002-04-02 2003-10-20 Northwestern University Peptide amphiphile solutions and self assembled peptide nanofiber networks
WO2003096972A2 (en) 2002-05-13 2003-11-27 Massachusetts Institute Of Technology Angiogenesis and cardiac tissue engineering with peptide hydrogels and related compositions and methods of use thereof
CA2387257C (en) 2002-05-23 2009-07-28 Suncor Energy Inc. Static deaeration conditioner for processing of bitumen froth
GB0216286D0 (en) 2002-07-15 2002-08-21 Univ Leeds Network
EP1542709A2 (en) 2002-08-06 2005-06-22 EPIX Pharmaceuticals, Inc. Peptide aggregates
DK1636250T3 (en) * 2003-06-25 2016-02-22 Massachusetts Inst Technology SELF-ORGANIZING PEPTIDES, CONTAINING MODIFICATIONS, AND APPLICATIONS THEREOF
US7713923B2 (en) * 2003-06-25 2010-05-11 Massachusetts Institute Of Technology Self-assembling peptides incorporating modifications and methods of use thereof
US7846891B2 (en) 2003-10-17 2010-12-07 Massachusetts Institute Of Technology Self-assembling peptides for regeneration and repair of neural tissue
GB0413346D0 (en) 2004-06-15 2004-07-21 Theryte Ltd Treating cancer
EP3031466B1 (en) * 2004-07-06 2018-11-28 3D Matrix, Inc. Purified amphiphilic peptide compositions and uses thereof
US7884185B2 (en) 2004-07-28 2011-02-08 University Of Delaware Hydrogels and uses thereof
US8039258B2 (en) 2004-09-28 2011-10-18 Ethicon, Inc. Tissue-engineering scaffolds containing self-assembled-peptide hydrogels
WO2006047315A2 (en) * 2004-10-25 2006-05-04 The Brigham And Women's Hospital, Inc. Targeted delivery of biological factors using self-assembling peptide nanofibers
CA2592292A1 (en) * 2005-01-04 2006-07-13 The Brigham And Women's Hospital, Inc. Sustained delivery of pdgf using self-assembling peptide nanofibers
ES2427565T3 (es) 2005-04-25 2013-10-31 Massachusetts Institute Of Technology Péptidos autoensambladores para promover la hemostasia
US9162005B2 (en) 2005-04-25 2015-10-20 Arch Biosurgery, Inc. Compositions for prevention of adhesions and other barrier applications
HUE037994T2 (hu) 2006-04-25 2018-09-28 Massachusetts Inst Technology Készítmények és eljárások szennyezõ anyagok, testfolyadékok vagy más anyagok mozgásának befolyásolására és/vagy más fiziológiai állapotok befolyásolására
US20070287741A1 (en) * 2006-06-13 2007-12-13 Uri Herzberg Compositions and methods for preventing or reducing postoperative ileus and gastric stasis in mammals
US20120085262A1 (en) 2010-08-26 2012-04-12 Freudenberg Forschungsdienste Kg Production of Highly Concentrated Solutions of Self-Assembling Proteins

Also Published As

Publication number Publication date
US20080274979A1 (en) 2008-11-06
ES2854674T3 (es) 2021-09-22
WO2008113030A3 (en) 2009-04-02
DK2146733T3 (da) 2021-01-11
WO2008113030A2 (en) 2008-09-18
JP2017105833A (ja) 2017-06-15
JP6112621B2 (ja) 2017-04-12
US20160324918A1 (en) 2016-11-10
CA2680824A1 (en) 2008-09-18
JP2010521495A (ja) 2010-06-24
EP2146733A2 (en) 2010-01-27
JP2013177467A (ja) 2013-09-09
EP2146733B1 (en) 2020-11-25
JP5860437B2 (ja) 2016-02-16
US9415084B2 (en) 2016-08-16
JP2015028086A (ja) 2015-02-12

Similar Documents

Publication Publication Date Title
US9415084B2 (en) Treatment of leaky or damaged tight junctions and enhancing extracellular matrix
US10682386B2 (en) Compositions for prevention of adhesions and other barrier applications
AU2006241123B2 (en) Compositions and methods for promoting hemostasis and other physiological activities
JP2010521495A5 (enExample)
HK1140431A (en) Treatment of leaky or damaged tight junctions and enhancing extracellular matrix
HK1140431B (en) Treatment of leaky or damaged tight junctions and enhancing extracellular matrix
HK1184397A (en) Compositions for prevention of adhesions and other barrier applications
HK1112847B (en) Self-assembling peptides for promoting hemostasis
HK1155356A (en) Compositions and methods for promoting hemostasis and other physiological activities
HK1184397B (en) Compositions for prevention of adhesions and other barrier applications

Legal Events

Date Code Title Description
EEER Examination request
H11 Ip right ceased following rejected request for revival

Free format text: ST27 STATUS EVENT CODE: T-6-6-H10-H11-H101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: TIME LIMIT FOR REVERSAL EXPIRED

Effective date: 20240916